Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3361237 · 3 trials · 3 indications
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY3361237 | EXPERIMENTAL | LY3361237 administered subcutaneously (SC). |
| Placebo | PLACEBO_COMPARATOR | Placebo administered SC. |
| LY3361237 - Subcutaneous (SC) | EXPERIMENTAL | LY3361237 administered SC |
| Placebo - SC | PLACEBO_COMPARATOR | Placebo administered SC |
| LY3361237 - Intravenous (IV) | EXPERIMENTAL | LY3361237 administered IV |
| Placebo - IV | PLACEBO_COMPARATOR | Placebo administered IV |
| Name | Type | Description |
|---|---|---|
| LY3361237 | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
| LY3361237 - SC | DRUG | LY3361237 administered SC |
| LY3361237 - IV | DRUG | LY3361237 administered IV |
| Placebo - SC | DRUG | Placebo administered SC |
| Placebo - IV | DRUG | Placebo administered IV |
Inclusion Criteria: * Have chronic plaque psoriasis for at least 6 months * Be willing and able to undergo skin biopsies * Body mass index (BMI) within the range of 18 to 40 kilograms per meter squared (kg/m²) * Female participants must agree to use birth control during the study Exclusion Criteri...
LY3361237 is an investigational small molecule being studied for systemic lupus erythematosus, psoriasis, and in healthy participants. It is in Phase 1 clinical development and is not approved by the FDA.
LY3361237 is being developed by Eli Lilly and Company, traded on the New York Stock Exchange under the ticker LLY.
LY3361237 is in Phase 1 clinical development. All three clinical trials listed for LY3361237 are Phase 1 studies and have been completed.
LY3361237 has been studied in three completed Phase 1 trials: NCT03695198 in healthy participants, NCT03933943 in participants with systemic lupus erythematosus, and NCT04975295 in participants with psoriasis.
LY3361237 is the only name provided for this investigational drug. No alternative names have been reported.